Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: North Eastern German Society of Gynaecological Oncology; North Eastern Germany Society of Gynaecologic Oncology
• Treatments: Topotecan

Criteria

Inclusion Criteria:

• patients with histologically-confirmed ovarian cancer

• relapse within 6 month after primary therapy

• primary therapy with platin and taxan

• ECOG 0-2

• >= 18 years

• leukocytes >= 3.000/ µl

• platelet >= 100.000/ µl

• neutrophil >= 1.500/ µl

• written informed consent

Exclusion Criteria:

• earlier topotecan therapy

• simultaneous or planned radiotherapy

• secondary malignancy